Abstract

Measures of lung function are heritable, and thus, we sought to utilise genetics to propose drug repurposing candidates that could improve respiratory outcomes. Lung function measures were found to be genetically correlated with seven druggable biochemical traits, with further evidence of a causal relationship between increased fasting glucose and diminished lung function. Moreover, we developed polygenic scores for lung function specifically within pathways with known drug targets and investigated their relationship with pulmonary phenotypes and gene expression in independent cohorts to prioritise individuals who may benefit from particular drug repurposing opportunities. A transcriptome-wide association study (TWAS) of lung function was then performed which identified several drug-gene interactions with predicted lung function increasing modes of action. Drugs that regulate blood glucose were uncovered through both the polygenic scoring and TWAS methodologies. In summary, we provided genetic justification for a number of novel drug repurposing opportunities that could improve lung function.

Data availability

All data are publicly available from the references described in the manuscript. Code related to this study can be found at the following link: https://github.com/Williamreay/Lung_function_drug_repurposing_manuscript

The following previously published data sets were used

Article and author information

Author details

  1. William R Reay

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    Competing interests
    William R Reay, has filed a patent related to the use of the pharmagenic enrichment score methodology in complex disorders. This competing interest only applies to that section of the manuscript. WIPO Patent Application WO/2020/237314..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7689-2453
  2. Sahar I El Shair

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  3. Michael P Geaghan

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  4. Carlos Riveros

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  5. Elizabeth G Holliday

    School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  6. Mark A McEvoy

    School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  7. Stephen Hancock

    School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  8. Roseanne Peel

    School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  9. Rodney J Scott

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  10. John R Attia

    School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
    Competing interests
    No competing interests declared.
  11. Murray J Cairns

    School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
    For correspondence
    murray.cairns@newcastle.edu.au
    Competing interests
    Murray J Cairns, has filed a patent related to the use of the pharmagenic enrichment score methodology in complex disorders. This competing interest only applies to that section of the manuscript. WIPO Patent Application WO/2020/237314..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2490-2538

Funding

National Health and Medical Research Council (1147644)

  • Murray J Cairns

National Health and Medical Research Council (1121474)

  • Murray J Cairns

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The use of the Hunter Community Cohort data was approved by the University of Newcastle Human Ethics Research Committee (HREC, reference: H-820-0504a). All other information related to ethical approval for the individual GWAS studies we utilised in this study are detailed in their respective publications as referenced throughout the text

Copyright

© 2021, Reay et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,459
    views
  • 172
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. William R Reay
  2. Sahar I El Shair
  3. Michael P Geaghan
  4. Carlos Riveros
  5. Elizabeth G Holliday
  6. Mark A McEvoy
  7. Stephen Hancock
  8. Roseanne Peel
  9. Rodney J Scott
  10. John R Attia
  11. Murray J Cairns
(2021)
Genetic association and causal inference converge on hyperglycaemia as a modifiable factor to improve lung function
eLife 10:e63115.
https://doi.org/10.7554/eLife.63115

Share this article

https://doi.org/10.7554/eLife.63115

Further reading

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Rashmi Sukumaran, Achuthsankar S Nair, Moinak Banerjee
    Research Article

    Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.

    1. Genetics and Genomics
    Wenjing Liu, Shujin Li ... Xianjun Zhu
    Research Article

    Familial exudative vitreoretinopathy (FEVR) is a severe genetic disorder characterized by incomplete vascularization of the peripheral retina and associated symptoms that can lead to vision loss. However, the underlying genetic causes of approximately 50% of FEVR cases remain unknown. Here, we report two heterozygous variants in calcyphosine-like gene (CAPSL) that is associated with FEVR. Both variants exhibited compromised CAPSL protein expression. Vascular endothelial cell (EC)-specific inactivation of Capsl resulted in delayed radial/vertical vascular progression, compromised endothelial proliferation/migration, recapitulating the human FEVR phenotypes. CAPSL-depleted human retinal microvascular endothelial cells (HRECs) exhibited impaired tube formation, decreased cell proliferation, disrupted cell polarity establishment, and filopodia/lamellipodia formation, as well as disrupted collective cell migration. Transcriptomic and proteomic profiling revealed that CAPSL abolition inhibited the MYC signaling axis, in which the expression of core MYC targeted genes were profoundly decreased. Furthermore, a combined analysis of CAPSL-depleted HRECs and c-MYC-depleted human umbilical vein endothelial cells uncovered similar transcription patterns. Collectively, this study reports a novel FEVR-associated candidate gene, CAPSL, which provides valuable information for genetic counseling of FEVR. This study also reveals that compromised CAPSL function may cause FEVR through MYC axis, shedding light on the potential involvement of MYC signaling in the pathogenesis of FEVR.